JP2014198718A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014198718A5 JP2014198718A5 JP2014109910A JP2014109910A JP2014198718A5 JP 2014198718 A5 JP2014198718 A5 JP 2014198718A5 JP 2014109910 A JP2014109910 A JP 2014109910A JP 2014109910 A JP2014109910 A JP 2014109910A JP 2014198718 A5 JP2014198718 A5 JP 2014198718A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibition
- activity
- pde7a
- pde7b
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000694 effects Effects 0.000 claims 23
- 230000005764 inhibitory process Effects 0.000 claims 21
- 208000016285 Movement disease Diseases 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 102100024233 High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A Human genes 0.000 claims 9
- 101001117267 Homo sapiens High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A Proteins 0.000 claims 9
- 101001117266 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 7B Proteins 0.000 claims 9
- 102100024232 cAMP-specific 3',5'-cyclic phosphodiesterase 7B Human genes 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 4
- 210000000653 nervous system Anatomy 0.000 claims 4
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 claims 3
- 229940123304 Phosphodiesterase 7 inhibitor Drugs 0.000 claims 3
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000002606 phosphodiesterase VII inhibitor Substances 0.000 claims 3
- 101100135868 Dictyostelium discoideum pde3 gene Proteins 0.000 claims 2
- 101100407335 Dictyostelium discoideum pde7 gene Proteins 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- 229960003638 dopamine Drugs 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 claims 1
- 102000004076 Dopamine D1 Receptors Human genes 0.000 claims 1
- 108090000511 Dopamine D1 Receptors Proteins 0.000 claims 1
- 229940098778 Dopamine receptor agonist Drugs 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 101150098694 PDE5A gene Proteins 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 101710122057 Phospholemman-like protein Proteins 0.000 claims 1
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 208000009106 Shy-Drager Syndrome Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 210000001640 nerve ending Anatomy 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 208000023515 periodic limb movement disease Diseases 0.000 claims 1
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 230000000946 synaptic effect Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92049607P | 2007-03-27 | 2007-03-27 | |
| US60/920,496 | 2007-03-27 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010501232A Division JP5580192B2 (ja) | 2007-03-27 | 2008-03-27 | 運動障害の処置のためのｐｄｅ７インヒビターの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014198718A JP2014198718A (ja) | 2014-10-23 |
| JP2014198718A5 true JP2014198718A5 (https=) | 2015-03-26 |
| JP5943964B2 JP5943964B2 (ja) | 2016-07-05 |
Family
ID=39789284
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010501232A Active JP5580192B2 (ja) | 2007-03-27 | 2008-03-27 | 運動障害の処置のためのｐｄｅ７インヒビターの使用 |
| JP2014109910A Active JP5943964B2 (ja) | 2007-03-27 | 2014-05-28 | 運動障害の処置のためのｐｄｅ７インヒビターの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010501232A Active JP5580192B2 (ja) | 2007-03-27 | 2008-03-27 | 運動障害の処置のためのｐｄｅ７インヒビターの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20080260643A1 (https=) |
| EP (1) | EP2139475B1 (https=) |
| JP (2) | JP5580192B2 (https=) |
| CN (2) | CN101917992A (https=) |
| AU (1) | AU2008230710B2 (https=) |
| CA (1) | CA2681650C (https=) |
| ES (1) | ES2533206T3 (https=) |
| MX (1) | MX2009010450A (https=) |
| NZ (1) | NZ580413A (https=) |
| RU (1) | RU2449790C2 (https=) |
| WO (1) | WO2008119057A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8637528B2 (en) * | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
| US8569512B2 (en) * | 2009-03-23 | 2013-10-29 | Merck Sharp & Dohme Corp. | P2X3 receptor antagonists for treatment of pain |
| FR2943673B1 (fr) * | 2009-03-27 | 2013-03-29 | Sanofi Aventis | Applications therapeutiques de derives de quinazolinedione |
| FR2944282B1 (fr) | 2009-04-09 | 2013-05-03 | Sanofi Aventis | Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques |
| FR2944206B1 (fr) | 2009-04-09 | 2012-12-28 | Sanofi Aventis | Applications therapeutiques dans le domaine cardiovasculaire de derives de quinazolinedione |
| AU2013202493B2 (en) * | 2009-05-04 | 2016-03-10 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
| ES2353093B1 (es) | 2009-05-20 | 2012-01-03 | Consejo Superior De Investigaciones Científicas (Csic) | Uso de derivados de quinazolinas y sus composiciones farmacéuticas en enfermedades neurodegenerativas. |
| ES2360783B1 (es) | 2009-10-02 | 2012-07-04 | Consejo Superior De Investigaciones Científicas (Csic) | 1,2,4-tiadiazoles-5-imino sustituidos utiles en el tratamiento de enfermedades neurodegenerativas |
| CN106038567A (zh) * | 2010-11-08 | 2016-10-26 | 奥默罗斯公司 | 使用pde7抑制剂治疗成瘾和冲动控制障碍 |
| US9220715B2 (en) | 2010-11-08 | 2015-12-29 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
| NZ628130A (en) * | 2012-05-07 | 2017-02-24 | Omeros Corp | Treatment of addiction and impulse-control disorders using pde7 inhibitors |
| IN2014DN10404A (https=) * | 2012-05-07 | 2015-08-14 | Omeros Corp | |
| CN109937038A (zh) * | 2016-08-26 | 2019-06-25 | 田边三菱制药株式会社 | 双环式含氮杂环化合物 |
| FI3846788T3 (fi) * | 2018-09-05 | 2025-12-17 | Univ Amsterdam | Pde11-estäjiä parkinsonin taudin hoitoon |
| US20260048059A1 (en) | 2022-08-18 | 2026-02-19 | Klaus Wirth | Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intoleranc |
| WO2024259383A2 (en) * | 2023-06-14 | 2024-12-19 | President And Fellows Of Harvard College | Ion channel binders and uses thereof |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5453566A (en) | 1986-03-28 | 1995-09-26 | Calgene, Inc. | Antisense regulation of gene expression in plant/cells |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| MC2115A1 (fr) | 1987-12-15 | 1991-07-05 | Gene Shears Pty Ltd | Ribozynes |
| GB8822492D0 (en) | 1988-09-24 | 1988-10-26 | Considine J | Apparatus for removing tumours from hollow organs of body |
| US5789573A (en) | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
| IL108367A0 (en) | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5739119A (en) | 1996-11-15 | 1998-04-14 | Galli; Rachel L. | Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA |
| US5932465A (en) * | 1997-10-16 | 1999-08-03 | Icos Corporation | Phosphodiesterase 8A |
| AU3307999A (en) * | 1998-02-23 | 1999-09-06 | Icos Corporation | Phosphodiesterase 10 |
| DK1018559T3 (da) * | 1998-12-23 | 2007-12-03 | Pfizer | Phosphodiesteraser |
| WO2000068230A1 (en) | 1999-05-05 | 2000-11-16 | Darwin Discovery Limited | 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7 inhibitors |
| AU4145200A (en) | 1999-05-07 | 2000-11-21 | Takeda Chemical Industries Ltd. | Cyclic compounds and uses thereof |
| US6146876A (en) | 1999-06-11 | 2000-11-14 | Millennium Pharmaceuticals, Inc. | 22025, a novel human cyclic nucleotide phosphodiesterase |
| US7491742B2 (en) * | 1999-10-21 | 2009-02-17 | Merck Patent Gmbh | Imidazole derivatives as phosphodiesterase VII inhibitors |
| DE19950647A1 (de) | 1999-10-21 | 2001-04-26 | Merck Patent Gmbh | Imidazolderivate als Phosphodiesterase VII-Hemmer |
| DE19953024A1 (de) * | 1999-11-04 | 2001-05-10 | Merck Patent Gmbh | Isoxazolderivate als Phosphodiesterase VII-Hemmer |
| DE19953025A1 (de) * | 1999-11-04 | 2001-05-10 | Merck Patent Gmbh | Pyrrolderivate als Phosphodiesterase VII-Hemmer |
| DE19953414A1 (de) * | 1999-11-06 | 2001-05-10 | Merck Patent Gmbh | Imidazopyridinderivate als Phospodiesterase VII-Hemmer |
| DE19954707A1 (de) * | 1999-11-13 | 2001-05-17 | Merck Patent Gmbh | Imidazolverbindungen als Phosphodiesterase VII-Hemmer |
| US6649592B1 (en) | 2000-01-14 | 2003-11-18 | Science & Technology Corporation @ Unm | Peptide inhibitors of LFA-1/ICAM-1 interaction |
| JP2003523405A (ja) * | 2000-02-22 | 2003-08-05 | セレジー カナダ インコーポレイテッド | 睡眠改善のための方法および組成物 |
| AU4415501A (en) | 2000-02-24 | 2001-09-03 | Bayer Aktiengesellschaft | Regulation of human gelatinase b-like enzyme 1 |
| GB0007934D0 (en) | 2000-03-31 | 2000-05-17 | Darwin Discovery Ltd | Chemical compounds |
| US7345031B2 (en) * | 2000-04-12 | 2008-03-18 | International Medical Innovations, Inc. | Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation and use |
| GB0015095D0 (en) | 2000-06-20 | 2000-08-09 | Celltech Chiroscience Ltd | Chemical compounds |
| MXPA03001717A (es) | 2000-08-30 | 2003-09-22 | Lilly Icos Llc | METODO PARA EL TRATAMIENTO DE LA MIGRAnA. |
| EP1193261A1 (en) | 2000-10-02 | 2002-04-03 | Warner-Lambert Company | New thiadiazoles and their use as phosphodiesterase-7 inhibitors |
| CZ20031334A3 (cs) * | 2000-11-14 | 2003-09-17 | Altana Pharma Ag | Isochinolinové deriváty a jejich použití jako inhibitory |
| AU2002224835A1 (en) | 2000-11-14 | 2002-05-27 | Byk Gulden Lomberg Chemische Fabrik G.M.B.H. | Dihydroisoquinolines as novel phosphodiesterase inhibitors |
| IL140844A0 (en) * | 2001-01-10 | 2002-02-10 | Polygene Ltd | Cationic polysaccharide compositions |
| EP1370211A4 (en) * | 2001-03-02 | 2005-02-09 | Bristol Myers Squibb Co | SIMULTANEOUS ADMINISTRATION OF MELANOCORTIN RECEPTOR AGONISTS AND A PHOSPHODIESTERASE HEMMER FOR THE TREATMENT OF DISEASES RELATED TO CYCLIC AMP |
| US6617357B2 (en) * | 2001-03-06 | 2003-09-09 | Smithkline Beecham Corporation | Compounds and their use as PDE inhibitors |
| AP1699A (en) | 2001-03-21 | 2006-12-26 | Warner Lambert Co | New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors |
| US6958328B2 (en) | 2001-04-18 | 2005-10-25 | Ortho-Mcneil Pharmaceutical, Inc | Arylindenopyridines and related therapeutic and prophylactic methods |
| CN1293074C (zh) | 2001-04-18 | 2007-01-03 | 奥索-麦克尼尔药品公司 | 具有pde抑制活性的芳基茚并吡啶 |
| US6903109B2 (en) * | 2001-04-18 | 2005-06-07 | Ortho-Muniel Pharmaceutical, Inc. | Arylindenopyridines and related therapeutic and prophylactic methods |
| US20030032579A1 (en) * | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| EP1385848A2 (en) | 2001-04-25 | 2004-02-04 | ALTANA Pharma AG | Phtalazinones derivatives useful as pde4/7 inhibitors |
| US20030053980A1 (en) | 2001-04-30 | 2003-03-20 | The Gillette Company | Shaving compositions containing highly lubricious water soluble polymers |
| MXPA03009925A (es) | 2001-04-30 | 2004-06-30 | Bayer Pharmaceuticals Corp | Nuevas tiofeno [2,3-d]pirimidinas 4-amino-5,6-sustituidas. |
| WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| DE60230266D1 (de) * | 2001-06-15 | 2009-01-22 | Astellas Pharma Inc | Phenylpyridincarbonyl piperazinderivate |
| CA2450934A1 (en) | 2001-06-19 | 2002-12-27 | Marco Dodier | Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
| PE20030008A1 (es) | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
| DE10130167A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Imidazotriazine |
| IL160307A0 (en) * | 2001-08-31 | 2004-07-25 | Univ Rockefeller | Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain |
| US20060286622A1 (en) * | 2001-09-28 | 2006-12-21 | Patricia Soulard | Polypeptides exhibiting PDE7 activity and their use for selecting compounds which inhibit PDE 7 enzyme activity |
| HU228316B1 (en) * | 2001-12-13 | 2013-03-28 | Daiichi Sankyo Company | Pyrazolopyrimidinone derivatives having pde7-inhibitory activity |
| DE10163991A1 (de) * | 2001-12-24 | 2003-07-03 | Merck Patent Gmbh | Pyrrolo-pyrimidine |
| WO2003057149A2 (en) | 2001-12-28 | 2003-07-17 | Bayer Corporation | 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones |
| TW200302726A (en) | 2002-01-31 | 2003-08-16 | Ono Pharmaceutical Co | Nitrogen-containing bicyclic compound and medicament containing same as active ingredient |
| US20040082061A1 (en) * | 2002-02-14 | 2004-04-29 | Anna Astromoff | Drug metabolizing enzymes |
| EP1348701A1 (en) | 2002-03-28 | 2003-10-01 | Warner-Lambert Company LLC | (2,4-disubstituted-thiazol-5-yl) amine compounds as PDE7 inhibitors |
| EP1348433A1 (en) | 2002-03-28 | 2003-10-01 | Warner-Lambert Company LLC | Thiazol-2-yl-imine compounds as PDE-7 inhibitors |
| EP1400244A1 (en) * | 2002-09-17 | 2004-03-24 | Warner-Lambert Company LLC | New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors |
| WO2004044196A1 (en) | 2002-11-13 | 2004-05-27 | Bayer Healthcare Ag | DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 7B (PDE7b) |
| ES2217956B1 (es) | 2003-01-23 | 2006-04-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo. |
| US7217527B2 (en) * | 2003-04-15 | 2007-05-15 | Vanderbilt University | Assay for phosphodiesterase function |
| JP2006219373A (ja) | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体 |
| JP2006219374A (ja) | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体 |
| WO2005018563A2 (en) * | 2003-08-22 | 2005-03-03 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury |
| WO2006004040A1 (ja) * | 2004-07-01 | 2006-01-12 | Daiichi Asubio Pharma Co., Ltd. | Ｐｄｅ７阻害作用を有するチエノピラゾール誘導体 |
| CA2599662A1 (en) * | 2005-03-01 | 2006-09-08 | Pfizer Limited | Use of pde7 inhibitors for the treatment of neuropathic pain |
| WO2006092692A1 (en) | 2005-03-01 | 2006-09-08 | Pfizer Limited | Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain |
| EP1940389A2 (en) * | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| RS20080233A (sr) * | 2005-12-02 | 2009-07-15 | Pfizer Limited, | Derivati spirocikličnog hinazolina kao inhibitori pde7 |
| US8637528B2 (en) * | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
-
2008
- 2008-03-27 JP JP2010501232A patent/JP5580192B2/ja active Active
- 2008-03-27 CN CN200880017058XA patent/CN101917992A/zh active Pending
- 2008-03-27 CN CN201510082785.6A patent/CN104758291B/zh active Active
- 2008-03-27 US US12/057,368 patent/US20080260643A1/en not_active Abandoned
- 2008-03-27 WO PCT/US2008/058530 patent/WO2008119057A2/en not_active Ceased
- 2008-03-27 AU AU2008230710A patent/AU2008230710B2/en active Active
- 2008-03-27 MX MX2009010450A patent/MX2009010450A/es active IP Right Grant
- 2008-03-27 ES ES08744515.1T patent/ES2533206T3/es active Active
- 2008-03-27 CA CA2681650A patent/CA2681650C/en active Active
- 2008-03-27 NZ NZ580413A patent/NZ580413A/xx unknown
- 2008-03-27 EP EP08744515.1A patent/EP2139475B1/en active Active
- 2008-03-27 RU RU2009138966/15A patent/RU2449790C2/ru active
-
2010
- 2010-12-21 US US12/974,693 patent/US20110091388A1/en not_active Abandoned
-
2014
- 2014-05-28 JP JP2014109910A patent/JP5943964B2/ja active Active
-
2018
- 2018-12-06 US US16/212,064 patent/US20190183824A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014198718A5 (https=) | ||
| CY1123460T1 (el) | Ενωσεις και μεθοδοι για τη θεραπεια μιας επιληπτικης διαταραχης | |
| RU2449790C2 (ru) | Использование ингибиторов pde7 для лечения нарушений движения | |
| MX375108B (es) | Compuestos y composiciones para la deteccion y el tratamiento de la enfermedad de alzheimer y trastornos relacionados. | |
| BR112015015477A2 (pt) | derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk | |
| MX369137B (es) | Crenolanib para el tratamiento de trastornos proliferativos que tienen flt3 mutado. | |
| BR112014017626A2 (pt) | métodos para tratar uma doença ou disfunção, métodos de identificação de um indivíduo, método para prever se um indivíduo com uma doença ou disfunção tem mais ou menos probabilidade para desenvolver toxicidade ao tratamento, método para determinar se um indivíduo com uma doença ou disfunção deve continuar ou suspender o tratamento que compreende um modulador de fgf19, método de otimização de eficácia terapêutica e método de ensaio | |
| Ide et al. | Role of NMDA receptor GluN2D subunit in the antidepressant effects of enantiomers of ketamine | |
| BR112015022472A2 (pt) | método e sistema para prever a resposta a tratamentos para transtornos mentais | |
| EP3207931A3 (en) | Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies | |
| BR112012028136A2 (pt) | terapia de combinaçao | |
| BR112015029090A2 (pt) | compostos de 3,4-di-hidroisoquinolin-2(1h)-ila | |
| EP2844256A4 (en) | TREATMENT OF NEURONAL DISEASES WITH TYROSINE CHINESE INHIBITORS | |
| HK1206264A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JOP20190008A1 (ar) | علاج ومنع اضطرابات النوم | |
| EA201170043A1 (ru) | Комбинация пилокарпина и метимазола для лечения заболевания шарко-мари-тута и связанных с ним нарушений | |
| MX382757B (es) | Inhibidor del sistema complemento de ornithodoros moubata para utilizarse en el tratamiento de enfermedades mediadas por el sistema complemento en pacientes con polimorfismo de c5. | |
| WO2013049725A3 (en) | Methods of using adenosine a1 receptor activation for treating depression | |
| BR112013001422A2 (pt) | metodo para tratar ou previnir disturbios induzidos por l-dopa, agonista dopamina e/ou acentuador de dopamina em um individuo que necessita dos mesmos, agente, composição, uso de ou mais agentes e metodo para tratar a doença de parkinson | |
| EA201691831A1 (ru) | Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов | |
| EA201691788A1 (ru) | Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов | |
| BR112014028446A2 (pt) | composto isolado, composição farmacêutica, método de tratamento ou prevenção de pelo menos um de doenças, distúrbios ou condições seguintes, e, método de tratamento ou prevenção de um distúrbio de ritmo circadiano ou distúrbio com um componente circadiano em um indivíduo | |
| Martin et al. | Selective kinase inhibitors as tools for neuroscience research | |
| FR3000896B1 (fr) | Forme galenique pour l'administration de principe(s) actif(s) permettant l'induction acceleree du sommeil et/ou le traitement des troubles du sommeil | |
| WO2009045900A3 (en) | Methods for treating or preventing diseases associated with low bone mass |